Galapagos Genomics Partners with Vertex in Gene Function Research | GenomeWeb

NEW YORK, Aug 22 – Galapagos Genomics is collaborating with Vertex Pharmaceuticals to identify the function of various proteins, the company announced Wednesday.

Galapagos, a privately held company based in Mechelen, Belgium, will provide Vertex with recombinant adenoviruses via its PhenoSelect expression platform. Vertex plans to use the information for characterization of protein activity within targeted biological pathways.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.